Preoperative CT anthropometric measurements and pancreatic pathology increase risk for postoperative pancreatic fistula in patients following pancreaticoduodenectomy

Yun Hwa Roh¹, Bo Kyeong Kang¹, Soon-Young Song¹, Chul-Min Lee¹, Yun Kyung Jung², Mimi Kim¹*  
¹ Department of Radiology, Hanyang University College of Medicine, Seoul, Republic of Korea, ² Department of Surgery, Hanyang University College of Medicine, Seoul, Republic of Korea  
* bluefish010@naver.com

Abstract

Postoperative pancreatic fistula (POPF) is a common complication following pancreaticoduodenectomy (PD). However, risk factors for this complication remain controversial. We conducted a retrospective analysis of 107 patients who underwent PD. POPF was diagnosed in strict accordance with the definition of the 2016 update of pancreatic fistula from the International Study Group on Pancreatic Fistula (ISGPF). Univariate and multivariate logistic regression analyses were performed to identify independent risk factors for POPF. A total of 19 (17.8%) subjects of pancreatic fistula occurred after PD, including 15 (14.1%) with grade B POPF and 4 (3.7%) with grade C POPF. There were 33 (30.8%) patients with biochemical leak. Risk factors for POPF (grade B and C) were larger area of visceral fat (odds ratio [OR], 1.40; \( p = 0.040 \)) and pathology other than pancreatic adenocarcinoma or pancreatitis (OR, 12.45; \( p = 0.017 \)) in the multivariate regression analysis. This result could assist the surgeon to identify patients at a high risk of developing POPF.

Introduction

Pancreaticoduodenectomy (PD) is a standard procedure for patients with benign or malignant tumors involving the head of the pancreas and peripancreatic regions [1–3]. Attributable to advancements in surgical techniques and perioperative management, the mortality rate after PD has improved significantly, reportedly reaching 1–2% at high volume centers [4–6]. However, the postoperative morbidity rate remains high, ranging from 27.1% to 43% [6–8].

Among the reported complications, postoperative pancreatic fistula (POPF) is the most common complication following PD and is associated with delayed gastric emptying, intra-abdominal abscess and hemorrhage, and superimposed infection and sepsis, consequently increasing the length of stay and even leading to reoperation in some cases [9–11]. Therefore, reducing the rate of POPF after PD is a serious challenge for clinicians.
Various risk factors for POPF have been suggested, including sex, body mass index (BMI), pancreatic duct size, pancreatic texture, blood transfusion, intraoperative blood loss, operation time, and visceral fat area [9,12,13]. However, definite causal factors for developing POPF after PD remain controversial. Recently, some studies have suggested a relationship between surgical outcomes and anthropometric measurements, such as the core muscle mass and body fat area. Depleted skeletal muscle mass and visceral obesity increased postoperative complications after total gastrectomy, major hepatectomy, and colorectal cancer [14–16]. With respect to PD, patients with sarcopenia and visceral obesity showed decreased survival and increased morbidity [12,17,18]. As the POPF criteria were updated in 2016, biochemical leak (POPF A) is no longer considered true POPF [19]. A few studies had reported on the association of anthropometric measurement with POPF according to the revised criteria [20,21].

In this study, we performed a retrospective study to evaluate the association and predictive value of anthropometric measurements and other pre- and perioperative variables for POPF.

**Methods**

**Subjects**

This retrospective study was approved by the institutional review board (IRB) of Hanyang University Hospital. All experiments were performed in accordance with the relevant guidelines and regulations.

One-hundred and twenty-four consecutive subjects who underwent PD between October 2007 and October 2017 were enrolled into this study. The exclusion criteria were as follows: lack of clinical information (hardness of pancreas [n = 9], BMI [n = 1]); interval between preoperative computed tomography (CT) and surgery >40 days (n = 3); unavailability of preoperative CT (n = 3); and difficulty evaluating POPF (n = 1). Finally, 107 subjects (male: female = 64:43; mean age, 65.9 years; range, 35–82 years) who underwent PD were included. Detailed information was obtained from electronic medical records. For each subject, the following data were collected: (1) subjects’ demographic and clinical features, including age, sex, BMI, preoperative albumin, and total bilirubin; (2) operative details, including pancreatic texture, operation time, performance of intraoperative blood transfusion, and the use of a pancreatic stent; and (3) final diagnosis of the tumor. The pancreatic texture of all subjects was examined by the surgeon during the operation and classified as either soft or hard. A pancreatic duct stent was occasionally used during reconstruction following PD according to the surgeon’s judgment. External drains were inserted in proximity to the pancreatic anastomosis for each surgery, and the amylase level of drain fluid was routinely measured during the inserted period.

**Measurement of anthropometric measurements**

We measured subjects’ abdominal circumference, visceral and subcutaneous fat, and total abdominal muscle area on preoperative CT scans at the level of the third lumbar vertebra (L3). Distinction among the muscle, fat, and different tissues was based on Hounsfield units (HU) using AquariusNET Server (TaraRecon, Foster City, CA, USA). A threshold range of -29 to 150 HU was used to define muscle and a range of -190 to -30 HU was used to define fat. Hand adjustment of the selected area was performed (Figs 1 and 2). Skeletal muscle mass was normalized for the subjects’ heights to calculate the skeletal muscle mass index (SMI, cm²/m²). The ratio of visceral fat to SMI (VF/SMI) was also calculated. Sarcopenia was defined as SMI ≤52.4 cm²/m² for men and ≤38.5 cm²/m² for women based on a study by Prado et al. These cutoff values are accepted by an international consensus group on the diagnostic criteria for cachexia associated with cancer [22,23]. Visceral obesity was defined as a visceral fat area ≥100
The risk factor for postoperative pancreatic fistula after pancreaticoduodenectomy
cm² in both sexes. This value is widely used as a cutoff to define sarcopenic obesity in Asian populations and is equivalent to that used for the diagnosis of metabolic syndrome in Japan [24,25].

**Definition of postoperative pancreatic fistula**

Pancreatic fistula was defined according to the revised 2016 International Study Group on Pancreatic Fistula (ISGPF) classification and grading [19]. The previous ‘grade A’ POPF is newly classified as ‘biochemical leak’, which refers to a transient and asymptomatic biochemical fistula. Grade B and C POPF are clinically relevant fistulae, which require a change in postoperative management. If peripancreatic drainage persists for more than 3 weeks or is repositioned through interventional procedures, it is classified as Grade B. Grade C POPF refers to those with POPF-related organ failure, reoperation, or death.

**Statistical analysis**

Normally distributed numerical variables are presented as mean and standard deviation (SD) and were compared using the independent t-test, and non-normally distributed numerical variables are presented as median (the first quartile–the third quartile) and were compared using the Mann-Whitney test. Categorical variables are presented as frequencies with percentage and were tested using the chi-squared test or Fisher’s exact test. Univariate logistic analysis and backward stepwise multivariate logistic regression analysis were performed to identify the independent risk factors for POPF after PD. Variables with P-values of <0.05 on univariate analyses were entered into the final multivariate model to reveal risk factors for POPF. For each parameter, an odds ratio (OR) for POPF was provided with a 95% confidence interval (CI). All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). P-values of <0.05 were considered statistically significant.

**Results**

Demographic and clinical characteristics are shown in Table 1. The median time interval between preoperative CT and surgery was 14 days (mean, 15 days; range, 3–40 days). A total of 19 (17.8%) patients developed a pancreatic fistula after PD, including 15 (14.1%) with grade B POPF, and 4 (3.7%) with grade C POPF. In this study, all patients with POPF C underwent reoperation. There were 33 (30.8%) patients with biochemical leak.

The area of visceral fat, VF/SMI ratio, pancreas hardness and pathology were significantly different between the two groups (Table 2). Subjects with POPF had a significantly larger area of visceral fat (159.6 cm² vs. 120.3 cm², p = 0.022), higher VF/SMI ratio (3.30 vs. 2.54, p = 0.030), more frequently had a soft pancreas (78.9% vs. 53.4%, p = 0.045), and more frequently had pathology other than pancreatic adenocarcinoma or pancreatitis (97.4% vs. 62.5%, p = 0.045) than patients without POPF. However, sex, BMI, pancreatic duct diameter, operation time, intraoperative blood transfusion and use of a pancreatic stent were not significantly different between the two groups.
Univariate regression analysis showed significant correlation between POPF and the following factors (Table 3): higher visceral fat (odds ratio [OR]: 1; 95% confidence interval [CI]: 1.00–1.02, \( p = 0.026 \)), higher VF/SMI ratio (OR: 1.46; 95% CI: 1.03–2.07; \( p = 0.036 \)), a soft texture of the pancreas (OR: 3.27; 95% CI: 1.01–10.64; \( p = 0.049 \)), and pathology other than pancreatic adenocarcinoma or pancreatitis (OR: 2.38; 95% CI: 1.38–84.69; \( p = 0.024 \)).

In the multivariate regression analysis, higher visceral fat (OR: 1.40; 95% CI: 1.07–15.43, \( p = 0.040 \)) and pathology other than pancreatic adenocarcinoma or pancreatitis (OR: 12.45; 95% CI: 1.59–99.28; \( p = 0.017 \)) were identified as independent risk factors for POPF (Table 4).

**Discussion**

Pancreatic fistula after PD remains a challenging problem, even in high-volume centers. Identification of patients at a high risk of developing pancreatic fistula helps in a more elaborate risk-benefit assessment before surgery and may allow clinicians to coordinate perioperative care. In our study, we observed POPF in 17.8% (19/107) of patients. Higher visceral fat and pathology other than pancreatic adenocarcinoma or pancreatitis were independent risk factors for developing POPF after PD.

Recently, studies regarding the effects of sarcopenia and visceral obesity on POPF have been conducted. To date, few studies have examined the impact of sarcopenic obesity on POPF.

Table 1. Baseline characteristics of subjects.

| Characteristics                      | No.   |
|--------------------------------------|-------|
| Demographic data                     |       |
| Subjects, no.                         | 107   |
| Age, years                           | 65.9 ± 9.9 |
| Male, no. (%)                        | 64 (59.8) |
| Body mass index, kg/m²               | 23.2 ± 3.0 |
| Final diagnosis, no. (%)             |       |
| Benign disease                       | 10 (9.3) |
| Chronic pancreatitis                 | 3     |
| Pseudocyst                           | 1     |
| Malignant disease                    | 97 (90.7) |
| CBD cancer                           | 34    |
| Pancreatic head cancer               | 31    |
| AOV cancer                           | 23    |
| Intraductal papillary mucinous neoplasm | 7   |
| Duodenal cancer                      | 2     |
| POPF, no. (%)                        |       |
| Absence                              | 55 (51.4) |
| Biochemical leak                     | 33 (30.8) |
| POPF grade B                         | 15 (14.1) |
| POPF grade C                         | 4 (3.7) |

Note. Data are presented as mean ± standard deviation or number of subjects with percentage in parentheses.

https://doi.org/10.1371/journal.pone.0243515.t001
survival in patients with pancreaticobiliary tumors [20,21,26,27]. Obesity and sarcopenia were synergistic and believed to exacerbate the risk of death, as well as the risk of metabolic disorders, and the number of related studies is increasing [28].

In our study, a larger area of visceral fat was significantly associated with POPF in both univariate and multivariate analyses, consistent with previous studies. The frequency of visceral obesity was higher in patients with POPF (84.2%, 16/19) compared to those without POPF (61.4%, 54/88), although it was not statistically significant. Percorali et al. also reported that the visceral fat area was an independent predictor of pancreatic fistula in patients undergoing PD [12]. Generally, patients with greater subcutaneous and visceral fat accumulation provide greater technical difficulty for surgeons. The view of the surgical field is deeper and poorer in obese patients, which may increase the risk of pancreatic fistula [14,29,30]. Other than}

Table 2. Subject demographics and clinical characteristics.

|                                | POPF (-) (n = 88) | POPF (+) (n = 19) | p-value |
|--------------------------------|------------------|------------------|---------|
| **Age, years**                 | 65.8 ± 9.9       | 65.9 ± 10.4      | 0.983   |
| **Sex**                        |                  |                  | 0.074   |
| Male, no. (%)                  | 49 (55.7)        | 15 (78.9)        |         |
| Female, no. (%)                | 39 (44.3)        | 4 (21.1)         |         |
| **Body mass index, kg/m²**     | 23.1 ± 2.9       | 23.9 ± 3.2       | 0.273   |
| **Preoperative albumin, g/dL** | 3.75 ± 0.52      | 3.9 ± 0.59       | 0.085   |
| **Preoperative total bilirubin, mg/dL (IQR)** | 1.73 (0.69–4.28) | 1.90 (0.58–5.80) | 0.453   |
| **Pancreatic duct diameter, mm (IQR)** | 3.5 (1–6)        | 2 (1–4)          | 0.858   |
| **Skeletal muscle index (SMI), cm²** | 46.9 ± 9.1       | 47.2 ± 9.8       | 0.902   |
| **Visceral fat (VF), cm²**     | 120.3 ± 62.2     | 159.6 ± 84.8     | 0.022 * |
| **Subcutaneous fat, cm²**      | 109.7 ± 59.3     | 104.3 ± 57.3     | 0.718   |
| **Abdominal circumference, cm**| 83.3 ± 8.5       | 87.3 ± 9.5       | 0.067   |
| **VF/SMI**                     | 2.54 ± 1.32      | 3.30 ± 1.57      | 0.030 * |
| **Sarcopenia, no. (%)**        |                  |                  | 0.493   |
| No                             | 40 (45.5)        | 7 (36.8)         |         |
| Yes                            | 48 (54.5)        | 12 (63.2)        |         |
| **Visceral obesity, no. (%)**  |                  |                  | 0.067   |
| No                             | 34 (38.6)        | 3 (15.8)         |         |
| Yes                            | 54 (61.4)        | 16 (84.2)        |         |
| **Pancreatic hardness, no. (%)** |                |                  | 0.045 * |
| Soft                           | 47 (53.4)        | 15 (78.9)        |         |
| Hard                           | 41 (46.6)        | 4 (21.1)         |         |
| **Operation time, minutes**    | 441 ± 71         | 476 ± 71         | 0.051   |
| **Transfusion, no. (%)**       |                  |                  | 0.481   |
| No                             | 54 (61.4)        | 10 (52.6)        |         |
| Yes                            | 34 (38.6)        | 9 (47.4)         |         |
| **Stent, no. (%)**             |                  |                  | 0.207   |
| No                             | 11 (12.5)        | 0                |         |
| Yes                            | 77 (87.5)        | 19 (100)         |         |
| **Pathology, no. (%)**         |                  |                  | 0.006 * |
| PDAC or pancreatitis           | 33 (37.5)        | 1 (5.3)          |         |
| Other pathology                | 55 (62.5)        | 18 (94.7)        |         |

Note. Data are presented as mean ± standard deviation, median with interquartile range, or number of subjects with percentage in parentheses. * are the parameters with p<0.05.

https://doi.org/10.1371/journal.pone.0243515.t002
mechanical reasons, excessive visceral fat is associated with insulin resistance [31] and comorbidities such as type 2 diabetes, atherosclerosis and cardiovascular disease [32,33], which may affect surgical outcomes negatively, including a higher rate of wound infection and anastomotic fistula and a longer hospital stay [30,34,35].

The skeletal muscle index and sarcopenia showed little association with POPF in this study. In a meta-analysis by Ratnayake et al., preoperative sarcopenia was not a significant negative predictive factor in postoperative morbidity, including POPF, following pancreatic resection [21]. On the contrary, there are several studies showing that sarcopenia is an independent risk factor for POPF [36,37]. Meanwhile, VF/SMI ratio was higher in POPF group than non-POPF group in our study, although it was not significant at multivariate analysis. High VF/SMI ratio could be referred to as sarcopenic obesity, a condition in which loss of muscle mass is accompanied by increase in fat accumulation [22]. Jang et al. also examined 284 patients who underwent PD between 2005 and 2016, concluded that sarcopenic obesity was the only predictor for POPF [20]. Although our study and study by Jang et al. used predefined cutoff for visceral obesity, sarcopenia, and sarcopenic obesity, an accurate definition of sarcopenic obesity has not

Table 3. Univariate risk factor analysis for postoperative pancreatic fistula.

| Variable                   | Odds ratio | 95% C.I.     | p-value |
|----------------------------|------------|--------------|---------|
| Sex [Female]               | 2.99       | 0.92, 9.72   | 0.069   |
| BMI                        | 1.1        | 0.93, 1.31   | 0.272   |
| Preoperative albumin       | 2.23       | 0.88, 5.63   | 0.9     |
| Preoperative total bilirubin| 1.06       | 0.94, 1.20   | 0.326   |
| Pancreatic duct diameter   | 0.99       | 0.86, 1.13   | 0.856   |
| SMI                        | 1          | 0.95, 1.06   | 0.901   |
| Visceral fat               | 1          | 1.00, 1.02   | 0.026*  |
| Subcutaneous fat           | 0.99       | 0.99, 1.01   | 0.715   |
| Abdominal circumference    | 1.56       | 0.99, 1.12   | 0.07    |
| VF/SMI                     | 1.46       | 1.03, 2.07   | 0.036*  |
| Sarcopenia [Absence]       | 0.7        | 0.25, 1.95   | 0.494   |
| Visceral obesity [Absence] | 0.3        | 0.08, 1.10   | 0.069   |
| Pancreatic hardness [Hard] | 3.27       | 1.01, 10.64  | 0.049*  |
| Operation time             | 1.01       | 1.00, 1.01   | 0.055   |
| Transfusion [Absence]      | 0.7        | 0.26, 1.90   | 0.483   |
| Stent [Absence]            | 0          | 0            | 0.999   |
| Pathology [PDAC or pancreatitis] | 2.38   | 1.38, 84.69  | 0.024*  |

Note. Reference categories are in square brackets.

* are the parameters with p<0.05.

https://doi.org/10.1371/journal.pone.0243515.t003

Table 4. Multivariable risk factor analysis for postoperative pancreatic fistula.

| Variable                   | Odds ratio | 95% C.I.     | p-value |
|----------------------------|------------|--------------|---------|
| Visceral fat               | 1.40       | 1.07, 15.43  | 0.040*  |
| Pathology [PDAC or pancreatitis] | 12.45 | 1.59, 99.28  | 0.017*  |

Note. Reference categories are in square brackets. C.I.: Confidence interval, VF/SMI: Visceral fat to skeletal muscle index ratio.

* are the parameters with p<0.05.

https://doi.org/10.1371/journal.pone.0243515.t004
yet been established. These various conclusions from existing studies suggest that the impact of sarcopenia and sarcopenic obesity in developing POPF following PD is still inconclusive and therefore further research is needed.

Higher POPF rate was observed in pathology other than PDAC or chronic pancreatitis, which was categorized according to the previously established fistula risk score criteria [38]. The mechanism by which pathologies other than PDAC or chronic pancreatitis increases the risk of POPF is related to the effect of soft pancreas parenchyma. Pathologies with pancreatic adenocarcinoma and chronic pancreatitis are more likely to result in hard parenchyma, therefore there could be a benefit in reducing the incidence of POPF. Hu et al. retrospectively analyzed 536 cases and also found that a soft pancreas was an independent risk factor for developing pancreatic fistula, including biochemical leak and POPF B and C, after PD (OR: 3.05, \( p < 0.001 \)) [9]. Kawai et al. reviewed 1,239 patients from 11 Japanese medical centers and concluded that a soft pancreas was a significant predictive factor for pancreatic fistula (OR: 2.7, \( p = 0.001 \)) [39]. In this study, among a total of 107 patients, a soft pancreas was more frequent in subjects with POPF than in those without POPF (78.9% vs. 53.4%), although the result was not significant at multivariable analysis. A soft pancreas is more prone to laceration when performing suturing and tying. Moreover, the soft texture of pancreatic remnants induces technical difficulties in performing pancreatoenteric and duct-to-mucosa anastomoses, which increase the risk of anastomotic leakage [40]. Although it is not possible to evaluate soft pancreas before surgery, the possibility of POPF can be assessed by guessing the pathology through preoperative CT.

Our study had several limitations. First, due to its retrospective nature, it may have been influenced by selection and information biases. Second, it is a single-center study, which only includes Koreans; therefore, the findings may not be applicable to other populations. Third, several surgical anastomotic techniques have been established in recent years, but the technique used in each surgery was not analyzed in this study. Also, the pancreatic texture during the operation was evaluated by the surgeon, which may be subjective. Studies related to quantitative measurement of pancreas texture have been reported, such as MR elastography or ultrasound elastography [41,42]. Further research regarding the objective assessment of the pancreas texture is warranted.

In conclusion, larger area of visceral fat and pathology other than pancreatic adenocarcinoma or pancreatitis are independent predictors of POPF after pancreaticoduodenectomy and may allow better preparation of the postoperative care for patients by identifying patients at a high risk of developing pancreatic fistulas.

Supporting information

S1 Dataset.
(XLSX)

S1 Table. Comparison of clinical characteristics in subjects with and without visceral obesity.
(DOCX)

Author Contributions

Conceptualization: Mimi Kim.

Data curation: Yun Hwa Roh, Yun Kyung Jung.

Formal analysis: Bo Kyeong Kang, Mimi Kim.
Methodology: Soon-Young Song, Chul-Min Lee.

Supervision: Mimi Kim.

Writing – original draft: Yun Hwa Roh.

Writing – review & editing: Mimi Kim.

References

1. Witkowski ER, Smith JK, Tseng JF. Outcomes following resection of pancreatic cancer. J Surg Oncol. 2013; 107(1):97–103. https://doi.org/10.1002/jso.23267 PMID: 22991309

2. Donahue TR, Reber HA. Surgical management of pancreatic cancer—pancreaticoduodenectomy. Semin Oncol. 2015; 42(1):98–109. https://doi.org/10.1053/j.seminoncol.2014.12.009 PMID: 25726055

3. Cameron JL, He J. Two thousand consecutive pancreaticoduodenectomies. J Am Coll Surg. 2015; 220(4):530–6. https://doi.org/10.1016/j.jamcollsurg.2014.12.031 PMID: 25724606

4. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006; 244(1):10–5. https://doi.org/10.1016/j.amcollsurg.2004.12.031 PMID: 16794383

5. Kimura W, Miyata H, Gotoh M, Hirai I, Kenjo A, Kitagawa Y, et al. A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system: the 30-day and in-hospital mortality rates for pancreaticoduodenectomy. Ann Surg. 2014; 259(4):773–80. https://doi.org/10.1097/SLA.0000000000000263 PMID: 24253151

6. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg. 2006; 10(9):1199–1211. https://doi.org/10.1016/j.j.gassurg.2006.08.018 PMID: 17114007

7. Schmidt CM, Powell ES, Yiannoutsos CT, Howard TJ, Wiebke EA, Wiesenauer CA, et al. Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg. 2004; 139(7):718–727. https://doi.org/10.1001/archsurg.139.7.718 PMID: 15249403

8. Assifi MM, Lindenmeyer J, Leiby BE, Grunwald Z, Rosato EL, Kennedy EP, et al. Surgical Apgar score predicts perioperative morbidity in patients undergoing pancreaticoduodenectomy at a high-volume center. J Gastrointest Surg. 2012; 16(2):275–281. https://doi.org/10.1007/s11605-011-1733-1 PMID: 22033701

9. Hu BY, Wan T, Zhang WZ, Dong JH. Risk factors for postoperative pancreatic fistula: Analysis of 539 successive cases of pancreaticoduodenectomy. World J Gastroenterol. 2016; 22(34):7797–7805. https://doi.org/10.3748/wjg.v22.i34.7797 PMID: 27678363

10. Reid-Lombardo KM, Farnell MB, Crippa S, Barnett M, Maupin G, Bassi C, et al. Pancreatic anastomotic leakage after pancreaticoduodenectomy in 1,507 patients: a report from the Pancreatic Anastomotic Leak Study Group. J Gastrointest Surg. 2007; 11(11):1451–1459. https://doi.org/10.1007/s11605-007-0270-4 PMID: 17710506

11. Goh BK, Tan YM, Chung YF, Chew PC, Ong HS, Chan WH, et al. Critical appraisal of 232 consecutive distal pancreatectomies with emphasis on risk factors, outcome, and management of the postoperative pancreatic fistula: a 21-year experience at a single institution. Arch Surg. 2008; 143(10):956–965. https://doi.org/10.1001/archsurg.143.10.956 PMID: 18936374

12. Pecorelli N, Carrara G, De Cobelli F, Cristel G, Damascelli A, Balzano G, et al. Effect of sarcopenia and visceral obesity on mortality and pancreatic fistula following pancreatic cancer surgery. Br J Surg. 2016; 103(4):434–442. https://doi.org/10.1002/bjs.10063 PMID: 26782301

13. Peng YP, Zhu XL, Yin LD, Zhu Y, Wei JS, Wu JL, et al. Risk factors of postoperative pancreatic fistula in patients after distal pancreatectomy: a systematic review and meta-analysis. Sci Rep. 2017; 7(1):185. https://doi.org/10.1038/s41598-017-00311-8 PMID: 28298641

14. Nishigori T, Tsunoda S, Okabe H, Tanaka E, Hisamori S, Hosogi H, et al. Impact of Sarcopenic Obesity on Surgical Site Infection after Laparoscopic Total Gastrectomy. Ann Surg Oncol. 2016; 23(Suppl 4):524–531. https://doi.org/10.1245/s10434-016-5385-y PMID: 27380646

15. Otsuji H, Yokoyama Y, Ebata T, Igami T, Sugawara G, Mizuno T, et al. Preoperative Sarcopenia Negatively Impacts Postoperative Outcomes Following Major Hepatectomy with Extrahepatic Bile Duct Resection. World J Surg. 2015; 39(6):1494–1500. https://doi.org/10.1007/s00268-015-2988-6 PMID: 25651963

16. Yang T, Wei M, He Y, Deng X, Wang Z. Impact of visceral obesity on outcomes of laparoscopic colorectal surgery: a meta-analysis. Anz J Surg. 2015; 85(7–8):507–513. https://doi.org/10.1111/ans.13132 PMID: 25902904
17. Onesti JK, Wright GP, Kenning SE, Tierney MT, Davis AT, Doherty MG, et al. Sarcopenia and survival in patients undergoing pancreatic resection. Pancreatology. 2016; 16(2):284–289. https://doi.org/10.1016/j.pan.2016.01.009 PMID: 26876798

18. Joglekar S, Asghar A, Mott SL, Johnson BE, Button AM, Clark E, et al. Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma. J Surg Oncol. 2015; 111 (6):771–775. https://doi.org/10.1002/jso.23862 PMID: 25563324

19. Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the International Study Group (ISGPI) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017; 161(3):584–591. https://doi.org/10.1016/j.surg.2016.11.014 PMID: 28040257

20. Jang M, Park HW, Huh J, Lee JH, Jeong YK, Nah YW, et al. Predictive value of sarcopenia and visceral obesity for postoperative pancreatic fistula after pancreatectoduodenectomy analyzed on clinically acquired CT and MRI. Eur Radiol. 2019; 29(5):2417–2425. https://doi.org/10.1007/s00330-018-5790-7 PMID: 30406311

21. Ratnayake CBB, Loveday BPT, Shrikhande SV, Windsor JA, Pandanaboyana S. Impact of preoperative sarcopenia on postoperative outcomes following pancreatic resection: A systematic review and meta-analysis. Pancreatology. 2018; 18(8):996–1004. https://doi.org/10.1016/j.pan.2018.09.011 PMID: 30287167

22. Prado CM, Liefers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008; 9(7):629–635. https://doi.org/10.1016/S1470-2045(08)70153-0 PMID: 18598529

23. Fearon K, Strasser F, Anker SD, Bossaeus I, Buera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12(5):489–495. https://doi.org/10.1016/S1470-2045(10)70218-7 PMID: 21296015

24. Lu CW, Yang KC, Chang HH, Lee LT, Chen CY, Huang KC. Sarcopenic obesity is closely associated with metabolic syndrome. Obes Res Clin Pract. 2013; 7(4):e301–e307. https://doi.org/10.1016/j.orcp.2012.02.003 PMID: 24306159

25. Lim KI, Yang SJ, Kim TN, Yoo HJ, Kang HJ, Song W, et al. The association between the ratio of visceral fat to thigh muscle area and metabolic syndrome: the Korean Sarcopenic Obesity Study (KSOS). Clin Endocrinol. 2010; 73(5):589–594. https://doi.org/10.1111/j.1365-2265.2010.03841.x.

26. Pacorelli N, Capreatti G, Sandini M, Damascelli A, Cristel G, De Cobelli F, et al. Impact of Sarcopenic Obesity on Failure to Rescue from Major Complications Following Pancreatectoduodenectomy for Cancer: Results from a Multicenter Study. Ann Surg Oncol. 2018; 25(1):308–317. https://doi.org/10.1245/s10434-017-6216-5 PMID: 29164940

27. Mintziras I, Miligkos M, Wachtler S, Manoharan J, Maurer E, Bartsch DK. Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: Systematic review and meta-analysis. Int J Surg. 2018; 59:19–26. https://doi.org/10.1016/j.ijsu.2018.09.014 PMID: 30266663

28. Zhang XM, Xie XH, Dou QL, Liu CY, Zhang WW, Yang YZ, et al. Association of sarcopenic obesity with the risk of all-cause mortality among adults over a broad range of different settings: a updated meta-analysis. Bmc Geriatr. 2019; 19(1):183. https://doi.org/10.1186/s12877-019-1195-y PMID: 31269909

29. Tranchart H, Gaujoux S, Rebours V, Vullierme MP, Dokmak S, Levy P, et al. Preoperative CT scan helps to predict the occurrence of severe pancreatic fistula after pancreatectoduodenectomy. Ann Surg. 2012; 256(1):139–145. https://doi.org/10.1097/SLA.0b013e318256c32c PMID: 22609844

30. Noun R, Riachy E, Ghonna C, Yazbeck T, Tohme C, Abboud B, et al. The impact of obesity on surgical outcome after pancreaticoduodenectomy. JOP. 2008; 9(4):468–476. PMID: 18648138

31. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006; 444(7121):881–887. https://doi.org/10.1038/nature05486 PMID: 17167477

32. Neeland IJ, Ross R, Despres JP, Matsuzawa Y, Yamashita S, Shai I, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019; 7 (9):715–725. https://doi.org/10.1016/S2213-8587(19)30084-1 PMID: 31301983

33. Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013; 93 (1):359–404. https://doi.org/10.1152/physrev.00033.2011 PMID: 23303813

34. Gaujoux S, Torres J, Olson S, Winston C, Gonen M, Brennan MF, et al. Impact of obesity and body fat distribution on survival after pancreatectoduodenectomy for pancreatic adenocarcinoma. Ann Surg Oncol. 2012; 19(9):2908–2916. https://doi.org/10.1245/s10434-012-2301-y PMID: 22411205

35. Park CM, Park JS, Cho ES, Kim JK, Yu JS, Yoon DS. The effect of visceral fat mass on pancreatic fistula after pancreatectoduodenectomy. J Invest Surg. 2012; 25(3):169–173. https://doi.org/10.3109/08941939.2011.616255 PMID: 22583019
36. Nishida Y, Kato Y, Kudo M, Aizawa H, Okubo S, Takahashi D, et al. Preoperative Sarcopenia Strongly Influences the Risk of Postoperative Pancreatic Fistula Formation After Pancreaticoduodenectomy. J Gastrointest Surg. 2016; 20(9):1586–1594. https://doi.org/10.1007/s11605-016-3146-7 PMID: 27126054

37. Centonze L, Di Sandro S, Lauterio A, De Carlis R, Botta F, Mariani A, et al. The Impact of Sarcopenia on Postoperative Course following Pancreatoduodenectomy: Single-Center Experience of 110 Consecutive Cases. Digest Surg. 2020; 37(4):312–320. https://doi.org/10.1159/000504703 PMID: 31958796

38. Callery MP, Pratt WB, Kent TS, Chaikof EL, Vollmer CM Jr. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatectoduodenectomy. J Am Coll Surg. 2013; 216(1):1–14. https://doi.org/10.1016/j.jamcollsurg.2012.09.002 PMID: 23122535

39. Kawai M, Kondo S, Yamaue H, Wada K, Sano K, Motoi F, et al. Predictive risk factors for clinically relevant pancreatic fistula analyzed in 1,239 patients with pancreatectoduodenectomy: multicenter data collection as a project study of pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepato-Bil-Pan Sci. 2011; 18(4):601–608. https://doi.org/10.1007/s00534-011-0373-x PMID: 21491103

40. Crippa S, Salvia R, Falconi M, Butturini G, Landoni L, Bassi C. Anastomotic leakage in pancreatic surgery. HPB (Oxford). 2007; 9(1):8–15. https://doi.org/10.1080/13651820600641357 PMID: 18333107

41. Kolipaka A, Schroeder S, Mo X, Shah Z, Hart PA, Conwell DL. Magnetic resonance elastography of the pancreas: Measurement reproducibility and relationship with age. Magn Reson Imaging. 2017; 42:1–7. https://doi.org/10.1016/j.mri.2017.04.015 PMID: 28476308

42. Kawabata Y, Okada T, Iijima H, Yoshida M, Iwama H, Xu JY, et al. Intraoperative Ultrasound Elastography Is Useful for Determining the Pancreatic Texture and Predicting Pancreatic Fistula After Pancreatocoduodenectomy. Pancreas. 2020; 49(6):799–805. https://doi.org/10.1097/MPA.0000000000001576 PMID: 32541635